Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory Shared mission of responsibly reintroducing psychedelic therapy to mental healthcare Hosting clinical trials for MDMA (MAPS Public Benefit Corporation), psilocybin (the Usona Institute), LSD (MindMed) and ketamine (the…


Previous articlePT310 – Omar Thomas – Vital Psychedelic Conversations
Next articleAwakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and Norway